⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 22, 2025

Supplementary Figure S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial

Janghee Woo Tingting Zhai Fang Yang Huilei Xu Margaret L. Healey Denise P. Yates Michael T. Beste David P. Steensma

View at Publisher

Ask AI

Bookmark

Share

Key Points

Cumulative incidence data demonstrates treatment-related differences in solid tumors among participants.
Findings indicate a variation in malignancy incidence based on the dose of canakinumab administered.
The analysis is rooted in data from the CANTOS randomized clinical trial involving clonal hematopoiesis.
Understanding these effects is crucial for tailoring cancer prevention strategies in at-risk populations.

Implication

Supplementary figure illustrates cumulative incidence of malignancies by canakinumab dose, suggesting treatment effects.

Abstract

Supplementary Figure S1 shows cumulative incidence of at least one malignancy by treatment, stratified by the canakinumab dose.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Woo et al. (2025) studied this question.

synapsesocial.com/papers/689a061be6551bb0af8cd945 https://doi.org/10.1158/1940-6207.29619082

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial2025
2Supplementary Figure S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial2024
3Supplementary Figure S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial2024
4Supplementary Figure S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial2025
5Supplementary Figure S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial2025

Supplementary Figure S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial2024
Supplementary Figure S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial2024
Data from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial2024